273 related articles for article (PubMed ID: 22957308)
1. Profiling of cytokines in human epithelial ovarian cancer ascites.
Matte I; Lane D; Laplante C; Rancourt C; Piché A
Am J Cancer Res; 2012; 2(5):566-80. PubMed ID: 22957308
[TBL] [Abstract][Full Text] [Related]
2. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
[TBL] [Abstract][Full Text] [Related]
3. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
Matte I; Garde-Granger P; Bessette P; Piché A
BMC Cancer; 2019 Apr; 19(1):406. PubMed ID: 31039761
[TBL] [Abstract][Full Text] [Related]
4. Stem-like tumor cells and proinflammatory cytokines in the ascitic fluid of ovarian cancer patients.
Gening SO; Abakumova TV; Antoneeva II; Rizvanov AA; Gening TP; Gafurbaeva DU
Klin Lab Diagn; 2021 May; 66(5):297-303. PubMed ID: 34047516
[TBL] [Abstract][Full Text] [Related]
5. Ascites IL-10 Promotes Ovarian Cancer Cell Migration.
Lane D; Matte I; Garde-Granger P; Bessette P; Piché A
Cancer Microenviron; 2018 Dec; 11(2-3):115-124. PubMed ID: 30039195
[TBL] [Abstract][Full Text] [Related]
6. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients.
Lane D; Matte I; Rancourt C; Piché A
BMC Cancer; 2011 May; 11():210. PubMed ID: 21619709
[TBL] [Abstract][Full Text] [Related]
8. Acidic ascites inhibits ovarian cancer cell proliferation and correlates with the metabolomic, lipidomic and inflammatory phenotype of human patients.
Yang Q; Bae G; Nadiradze G; Castagna A; Berezhnoy G; Zizmare L; Kulkarni A; Singh Y; Weinreich FJ; Kommoss S; Reymond MA; Trautwein C
J Transl Med; 2022 Dec; 20(1):581. PubMed ID: 36503580
[TBL] [Abstract][Full Text] [Related]
9. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
10. Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation.
Atkins GJ; Haynes DR; Geary SM; Loric M; Crotti TN; Findlay DM
Bone; 2000 Jun; 26(6):653-61. PubMed ID: 10831938
[TBL] [Abstract][Full Text] [Related]
11. Expression of IL-10 in patients with ovarian carcinoma.
Mustea A; Könsgen D; Braicu EI; Pirvulescu C; Sun P; Sofroni D; Lichtenegger W; Sehouli J
Anticancer Res; 2006; 26(2C):1715-8. PubMed ID: 16617566
[TBL] [Abstract][Full Text] [Related]
12. Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks.
Naldini A; Morena E; Belotti D; Carraro F; Allavena P; Giavazzi R
Thromb Haemost; 2011 Oct; 106(4):705-11. PubMed ID: 21833453
[TBL] [Abstract][Full Text] [Related]
13. CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling.
Lane D; Matte I; Laplante C; Garde-Granger P; Carignan A; Bessette P; Rancourt C; Piché A
Mol Cancer; 2016 Sep; 15(1):58. PubMed ID: 27613122
[TBL] [Abstract][Full Text] [Related]
14. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer.
Yigit R; Figdor CG; Zusterzeel PL; Pots JM; Torensma R; Massuger LF
Eur J Cancer; 2011 Aug; 47(12):1883-9. PubMed ID: 21514148
[TBL] [Abstract][Full Text] [Related]
15. Cytokines in peritoneal fluid of ovarian neoplasms.
de Lima CA; Silva Rodrigues IS; Martins-Filho A; Côbo Micheli D; Martins Tavares-Murta B; Candido Murta EF; Simões Nomelini R
J Obstet Gynaecol; 2020 Apr; 40(3):401-405. PubMed ID: 31476946
[TBL] [Abstract][Full Text] [Related]
16. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
[TBL] [Abstract][Full Text] [Related]
17. Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients.
Hoogstad-van Evert JS; Maas RJ; van der Meer J; Cany J; van der Steen S; Jansen JH; Miller JS; Bekkers R; Hobo W; Massuger L; Dolstra H
Oncotarget; 2018 Oct; 9(78):34810-34820. PubMed ID: 30410679
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of abdominal fluid cytokine levels in ovarian hyperstimulation syndrome (OHSS).
Farkas B; Boldizsar F; Bohonyi N; Farkas N; Marczi S; Kovacs GL; Bodis J; Koppan M
J Ovarian Res; 2020 Mar; 13(1):25. PubMed ID: 32138790
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
[TBL] [Abstract][Full Text] [Related]
20. Clinical Relevance of Mortalin in Ovarian Cancer Patients.
Rajtak A; Czerwonka A; Pitter M; Kotarski J; Okła K
Cells; 2023 Feb; 12(5):. PubMed ID: 36899836
[No Abstract] [Full Text] [Related]
[Next] [New Search]
